Glenview Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Glenview Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-158,301	Closed	-$18.8M	–	66
2022 Q1	$18.8M	Buy	158,301 +466	+0.3%	+$58.1K	0.38%	43
2021 Q4	$21.8M	Buy	157,835 +43,490	+38%	+$5.53M	0.46%	43
2021 Q3	$15.9M	Sell	114,345 -330,356	-74%	-$41.2M	0.29%	51
2021 Q2	$43.2M	Sell	444,701 -13,899	-3%	-$1.13M	0.71%	42
2021 Q1	$31.3M	Buy	+458,600	New	+$37.1M	0.53%	45
2020 Q4	–	Sell	-97,047	Closed	-$6.31M	–	58
2020 Q3	$6.31M	Sell	97,047 -23,285	-19%	-$1.53M	0.2%	42
2020 Q2	$8.8M	Buy	+120,332	New	+$6.4M	0.24%	39

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Glenview Capital Management's BHVN Position: Q2 2022 in Review

Glenview Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 158,301 shares — an estimated $18.8M sold.

Glenview Capital Management first reported a position in BHVN in Q2 2020 and held it in 7 quarters. The position peaked at $43.2M in Q2 2021. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

Glenview Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
Glenview Capital Management sold 158,301 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $18.8M.
Glenview Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2020 and held it in 7 quarters.
Glenview Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $43.2M in Q2 2021.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Glenview Capital Management's 13F filing for Q2 2022, filed 11 Aug 2022.